



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	328536	ETHICAL NUTRIENTS IMMUNE FIGHTER
ARTG entry for	Medicine Listed	
Sponsor	Metagenics (Aust) Pty Ltd	
Postal Address	PO Box 675, VIRGINIA BC, QLD, 4014 Australia	
ARTG Start Date	14/01/2020	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . ETHICAL NUTRIENTS IMMUNE FIGHTER

Product Type	Single Medicine Product	Effective Date	14/01/2020
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Traditionally used in Ayurvedic medicine to aids/assists with recovery from illness/convalescence

Maintain/support healthy immune system function

Traditionally used in Chinese medicine to maintain/support healthy immune system function

Traditionally used in Chinese medicine to maintain/support immune system to fight illness

Maintain/support immune system to fight illness

Traditionally used in Ayurvedic medicine to support healthy body stress recovery

Traditionally used in Chinese medicine to decrease/reduce/relieve the severity of symptoms of mild upper respiratory tract infections

Traditionally used in Chinese medicine to decrease/reduce/relieve the severity of common cold symptoms

Traditionally used in Chinese medicine to decrease/reduce/relieve symptoms of common cold

Indication Requirements

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to serious immunological diseases.

Product presentation must not imply or refer to serious forms of respiratory disorders/diseases, such as: asthma, pneumonia, COAD, COPD, influenza.

Label statement: Adults only, OR Not to be used in children under 2 years of age without medical advice (or words to that effect).

Product presentation must not imply or refer to chronic fatigue syndrome.

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Respiratory tract infections must be qualified by 'mild'.

Standard Indications



Australian Government
Department of Health and Aged Care
 Therapeutic Goods Administration

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet.

Additional Product information

Pack Size/Poison information

Pack Size **Poison Schedule**

Components

1 . Formulation 1

Dosage Form Tablet, film coated

Route of Administration Oral

Visual Identification

Active Ingredients

betacarotene	5.4 mg
colecalfiferol	.01 mg
Ganoderma lucidum fruiting body Extract dry concentrate	353 mg
Equivalent: Ganoderma lucidum (Dry)	6 g
Lentinula edodes fruiting body Extract dry concentrate	375 mg
Equivalent: Lentinula edodes (Dry)	6 g
Withania somnifera root Extract dry concentrate	240 mg
Equivalent: Withania somnifera (Dry)	6 g
zinc amino acid chelate	70 mg
Equivalent: zinc	14 mg

Other Ingredients (Excipients)

- Acacia
- citric acid
- crospovidone
- dl-alpha-tocopherol
- hypromellose
- liquid glucose
- macrogol 400
- magnesium stearate
- maize starch
- medium chain triglycerides
- microcrystalline cellulose
- silicon dioxide
- sodium ascorbate
- starch sodium octenyl succinate
- sucrose

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.